Summary: GLP-1 receptor agonists—widely prescribed drugs such as Ozempic and Wegovy for diabetes and weight management—may also offer unanticipated benefits for people with chronic migraine.
A preliminary, observational analysis found that people with chronic migraine who started GLP-1 drugs had fewer emergency department visits and hospital admissions and were less likely to escalate to additional acute or preventive migraine therapies compared with similar patients who began topiramate, a common migraine preventive. Researchers suggest these metabolic agents could help stabilize migraine burden, possibly through anti-inflammatory and neurovascular effects in addition to weight loss.
Key Facts
- Fewer emergency visits: GLP-1 users were about 10% less likely to visit the emergency department within one year.
- Reduced hospitalizations: Hospital admission risk over one year was approximately 14% lower among GLP-1 users.
- Less reliance on acute or advanced therapies: People starting GLP-1 drugs were roughly 13% less likely to receive triptans or undergo nerve block procedures. They were also significantly less likely to begin newer or more intensive preventive treatments—42% less likely to start CGRP monoclonal antibodies and 23% less likely to start gepants.
- Large, matched cohorts: The study compared about 11,000 people who began GLP-1 receptor agonists with another 11,000 who began topiramate, matching participants on age, body mass index, prior health conditions, and prior migraine treatments.
- GLP-1 drugs included: liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide and albiglutide.
Source: AAN
Overview: In a retrospective health-record analysis presented at the American Academy of Neurology’s 78th Annual Meeting (April 18–22, 2026), investigators examined whether people with chronic migraine who started GLP-1 receptor agonists for other indications experienced different clinical outcomes than those beginning topiramate. Chronic migraine was defined as headache on at least 15 days per month for three months, with at least eight days per month featuring migraine symptoms such as throbbing pain, nausea, or light sensitivity.
Researchers identified people with a recorded chronic migraine diagnosis who had started a GLP-1 drug within a year of that diagnosis and compared them to matched patients who initiated topiramate in the same timeframe. Matching factors included age, BMI, comorbidities and previous migraine treatment patterns. The analysis tracked outcomes for one year after drug initiation using electronic medical records, capturing emergency department visits, hospitalizations, nerve block procedures and new prescriptions for acute and preventive migraine medications.
After adjustment, 23.7% of patients starting GLP-1 drugs visited the emergency department over the year compared with 26.4% of those starting topiramate. GLP-1 recipients were roughly 10% less likely to have an emergency department visit, 14% less likely to be hospitalized, and about 13% less likely to receive a triptan or undergo a nerve block procedure. In addition, initiation of several preventive medication classes was lower among GLP-1 users: valproate (48% lower), CGRP monoclonal antibodies (42% lower), tricyclic antidepressants (35% lower), and gepants (23% lower). There was no significant difference in initiation of beta blockers.
The findings are associative and do not establish causation. As an observational study, it could not fully account for changes during the follow-up year—such as weight loss, shifts in migraine frequency or severity, medication adherence, or lifestyle changes—that might influence outcomes. The authors note that chronic migraine frequently coexists with metabolic and inflammatory conditions like obesity, insulin resistance, sleep apnea and depression, which can complicate treatment and outcomes.
Study author Vitoria Acar, MD, from the University of Sao Paulo, commented that people with chronic migraine often require multiple attempts to find an effective preventive medication and may visit the emergency room for severe attacks. Observing lower emergency care use and reduced escalation to additional acute or preventive therapies among GLP-1 users suggests these drugs could be stabilizing migraine burden through mechanisms beyond weight loss—potentially anti-inflammatory and neurovascular effects mediated by GLP-1 receptors in the brain and blood vessels.
Limitations and next steps: Because the study cannot prove causality, clinical trials specifically designed to test GLP-1 receptor agonists for migraine prevention and management are required before these agents can be recommended for that indication. Future research should measure changes in weight, migraine frequency and severity, and other confounding factors over time to clarify whether observed associations reflect direct drug effects on migraine biology.
Funding: The research was supported by patient philanthropy and Miles for Migraine.
Key Questions Answered:
A: Not at this time. GLP-1 receptor agonists are approved for diabetes and weight management. This study reports an association, not proof of benefit for migraine. Randomized clinical trials targeting migraine are needed before prescribing GLP-1s for this purpose becomes standard practice.
A: Weight loss can reduce migraine frequency for some people, but researchers believe additional mechanisms may be involved. GLP-1 receptors exist in the brain and vasculature, and these drugs may exert anti-inflammatory or neurovascular effects that reduce migraine susceptibility independently of weight change.
A: In this analysis, people who began GLP-1 therapy were less likely to escalate to more costly or invasive options (such as CGRP antibodies or nerve blocks) than those who started topiramate, suggesting greater overall stability of care. However, direct comparative clinical trials are required to determine relative effectiveness and safety for migraine management.
Editorial Notes:
- Edited by a Neuroscience News editor.
- Journal paper reviewed in full by the editorial team.
- Additional context provided by staff.
About this neuropharmacology and migraine research news
Author: Renee Tessman
Source: AAN
Contact: Renee Tessman – AAN
Image: The image is credited to Neuroscience News
Original Research: The findings will be presented at the American Academy of Neurology’s 78th Annual Meeting.